Skip to main content

4 Result(s)

within Chapter Remove this filter Pierre Fenaux Remove this filter

and

  1. No Access

    Chapter and Conference Paper

    Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen

    EMA 86 regimen, associating mitoxantrone, 12 mg/m2/day on days 1–3, etoposide, 200 mg/m2/day as a continuous infusion on days 8–10 and cytarabine, 500 mg/m2/day as a continuous infusion on days 1–3 and 8–10, was ...

    Eric Archimbaud, Xavier Thomas, Véronique Leblond… in Acute Leukemias V (1996)

  2. No Access

    Chapter

    Burkitt’s Acute Lymphoblastic Leukemia (L3ALL) in Adults

    Accounting for 1–3% of all cases of acute lymphoblastic leukemias (ALL), Burkitt cell ALL (L3ALL) is characterized by the morphology of blast cells, the presence of monoclonal surface immunoglobulins (sIg), and b...

    Vincent Ribrag, Philippe Casassus, Pierre Fenaux in Acute Leukemias (2008)

  3. No Access

    Chapter

    Treatment with Hypomethylating Agents (HMA)

    In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-n...

    Ulrich Germing, Pierre Fenaux in Myelodysplastic Syndromes (2018)

  4. No Access

    Chapter

    Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome

    Lower-risk myelodysplastic syndromes (MDS) include patients with very low, low, and part of intermediate revised IPSS (i.e., a score below 4), characterized by a low risk of progression to AML, but often promi...

    Pierre Fenaux, Lionel Adès in Diagnosis and Management of Myelodysplastic Syndromes (2020)